MRNA
$51.38-0.99 (-1.89%)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influe...
Recent News
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review
In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 PDUFA date for its seasonal flu vaccine, complementing the commercial rollout of its RSV shot and ongoing cost-cutting efforts. Together, these developments highlight Moderna’s shift from a single COVID-19 product story toward a broader oncology and respiratory vaccine portfolio supported by tighter...
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
They aren't just "pandemic stocks."